Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.
Hosted on MSN22h
How a Salty Diet Might Increase Your Risk of Dry, Itchy Skin
The study, out of the University of California, San Francisco (UCSF), and the University of California, Berkeley, discovered a significant correlation between high-sodium diets and developing atopic ...
healthday on MSN4h
Breathing Dirty Air Might Raise Eczema Risks
Cases of the autoimmune skin condition eczema appear to rise in areas most plagued by air pollution, new research show ...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
dermatologyadvisor6h
Greater Fine Particulate Matter Linked to Increased Odds of Eczema
The odds of eczema are increased with greater exposure to fine particulate matter of diameter ≤2.5 μm, according to study findings.